Original Research Paper

Volume - 16 | Issue - 07 | July - 2026 | PRINT ISSN No. 2249 - 555X | DOI : 10.36106/ijar

Health Care

PMOS AS A LIFESTYLE DISORDER THROUGH AYURVEDIC LENS:A COMPREHENSIVE CLINICAL & HISTORICAL INTEGRATION FRAMEWORK

Dr Rahul Chauhan* Assistant Professor, Department of Swathavritta and Yoga, IIMT Ayurvedic Medical College and Hospital *Corresponding Author

Dr K.Sharmila Associate Professor, Department of Prasuti Tantra and Stree Roga, IIMT Ayurvedic Medical College and Hospital

ABSTRACT PMOS as a lifestyle disorder through Ayurvedic lens. A generation of young women is silently struggling with irregular cycles, unexplained weight gain, acne, infertility, anxiety, and metabolic dysfunction—often labeled under the confusing umbrella of PCOD or PCOS. Polyendocrine metabolic ovarian syndrome is a common endocrine-metabolic disorder affecting 6-10% of reproductive-age women, characterized by menstrual irregularity, anovulation, hyperandrogenism, insulin resistance, and metabolic disturbances such as obesity and dyslipidemia. Modern medicine attributes its etiology to genetic predisposition, lifestyle factors, hypothalamic-pituitary-ovarian axis dysfunction, and insulin resistance leading to hyperandrogenism. Despite advances in pharmacological management, long-term control remains challenging due to recurrence and multisystem involvement. This article aims to give elaborate description of PMOS ,its historical origin,pathophysiology, diagnostic criteria,clinical presentation and management with classical Ayurvedic concepts and propose a holistic management framework. A review of Ayurvedic texts such as Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya, and Kashyapa Samhita was conducted alongside contemporary literature. PCOS does not have a direct reference in classics but its features align with multiple Ayurvedic disorders. Etiologically it can be understood as a Santarpanajanya Vyadhi resulting from Avyayama, Divaswapna, Guru-Snigdha-Madhura Ahara, and Manasika factors like Chinta and Shoka, which parallels the modern concept of sedentary lifestyle and metabolic syndrome. Pathogenesis involves vitiation of Kapha and Vata, impairment of Jatharagni and Dhatvagni, Ama formation, and Avarana of Vata by Kapha and Meda in Artavaha Srotas leading to Srotorodha. Clinically, oligomenorrhea and amenorrhea correlate with Artava Kshaya and Nashtartava, anovulatory infertility with Vandhya and Pushpaghni Jataharini Vyapad, obesity with Sthoulya, insulin resistance with Prameha, while acne and hirsutism correspond to Mukhadooshika and Atirurlomata. Thus PMOS is a Bahudosha, Dhatu Pradoshaja condition involving Rasa, Rakta, Mamsa, and Meda Dhatus with Agni Mandhya as the central pathology. The Ayurvedic approach focuses on Agni Deepana, Ama Pachana, Srotoshodhana, Kapha-Vata Shamana, Medohara, and Artava Janana measures along with Ahara-Vihara modification, which can complement modern therapy for sustainable management.

KEYWORDS : Polyendocrine Metabolic Ovarian Syndrome , Artava Dusti, Insulin Resistance, Samprapti, Metabolic Syndrome

INTRODUCTION

Evolution of the Terminology

Many women experience irregular cycles, unexplained weight gain, acne, infertility, anxiety, and metabolic dysfunction. This constellation of symptoms is frequently diagnosed as Polycystic Ovary Syndrome (PCOS) or Polycystic Ovarian Disease (PCOD) [1].

The nomenclature for this endocrine condition has evolved over time, reflecting advances in diagnostic technology and a shift from localized anatomical classification to systemic understanding [2, 4, 3].

- **The Anatomical Paradigm (1930s–1980s):** In 1935, Stein and Leventhal formally described the condition as a clinical triad: amenorrhea, hirsutism, and bilaterally enlarged ovaries. It was initially labeled Stein-Leventhal Syndrome, later transitioning to Polycystic Ovary Disease (PCOD) [5, 6, 7]. This era conceptualized the condition via a strict gynecological and surgical lens, assuming a static pathology localized to the ovarian stroma [7].
- **The Syndromic Paradigm (1990s–2026):** Radioimmunoassays and transvaginal ultrasonography advanced during this period. Clinicians realized anatomical alterations constituted secondary manifestations of a broader endocrine imbalance [8, 4]. The transition to Polycystic Ovary Syndrome (PCOS) identified a symptom cluster: reproductive axis failure and hyperandrogenism [9, 10].
- **The Network Medicine Paradigm (2026 onward):** The modern shift to Polyendocrine Metabolic Ovarian Syndrome (PMOS) constitutes a critical epistemological advancement [11]. It strips away organ-specific biases to codify the condition as a lifelong, multi-systemic metabolic disorder driven by neuroendocrine and metabolic network failures [11].

The "Anatomical Trap" vs. "Network Medicine"

This transition reflects modern medicine's shift from localized, organ-based pathology to Systems Biology and network medicine [7]. Stein and Leventhal (1935) were limited by contemporary diagnostic tools, relying heavily on manual physical examination and exploratory surgery. Consequently, they defined the condition by the observable macro-morphology of the ovary [4].

For nearly a century, naming the condition after an organ (the ovary) and a structural feature (cysts) created a cognitive bias [10]. This biased clinical perception framed the ovary as the disease origin rather than an organ under siege by systemic factors [11]. The PMOS paradigm reframes the ovary as a downstream target of a wider network failure, positioning it as an innocent bystander to systemic neuroendocrine and metabolic cross-talk [12].

The Epistemic Shift in the Acronym

The structural timeline below visually demonstrates how the diagnosis expands at each evolutionary stage [13]:

- **PCOD (1930s)** ⟶ Focused purely on the Macro-Anatomy of the Ovary [14]
- **PCOS (1990s)** ⟶ Expanded to a Syndromic Cluster (Reproductive + Endocrine) [15]

Why PMOS is Now Preferred Globally

International guidelines initiated discussions for renaming Polycystic Ovary Syndrome (PCOS) to address its complex etiology [16]. While the traditional acronym remains widely recognized, the new nomenclature demonstrates a growing global preference based on three critical clinical and academic factors [17]:

- **Correction of the "Cyst" Misnomer:** The term "polycystic" is fundamentally inaccurate [18]. Ultrasound imaging reveals fluid-filled structures that are not true pathological cysts (i.e., tissue-damaging, neoplastic, or inflammatory lesions) [19]. Instead, these structures represent healthy antral follicles with arrested mid-cycle maturation due to anovulation [20]. This misnomer generated patient anxiety and clinical mismanagement, including unnecessary surgical wedge resections [21].
- **De-siloing from Gynecological Medicine:** The primary modifier "Ovary" within the PCOS term confined the condition to reproductive medicine [22]. This resulted in a widespread clinical blindspot: patient management frequently occurred only during active fertility treatment [23]. Proposed new nomenclature integrates "Polyendocrine" and "Metabolic" into the diagnostic title [24]. This advocates for lifelong cardiometabolic and endocrine prophylaxis, moving beyond reactive fertility care [25, 23].
- **Elimination of Diagnostic Exclusionary Errors:** The old framework frequently dismissed or delayed diagnosis for patients with severe insulin resistance, metabolic syndrome, and

hyperandrogenism who presented with morphologically normal ovaries on ultrasound [26]. Evolving diagnostic approaches recognize that a normal pelvic ultrasound does not preclude the condition if systemic endocrine and metabolic criteria are met [27].

The Epistemological Difference: Syndrome vs. Disease

Clinical nosology (disease classification) establishes a critical syndrome-disease distinction that dictates profound diagnostic and therapeutic implications [28].

Disease Configuration: Specific Etiology ⟶ Distinct Pathophysiology ⟶ Direct Cure [29]

Syndrome Configuration: Multiple Drivers ⟶ Divergent Pathways ⟶ Spectrum Presentation [30]

Table1: Difference Between PCOD and PCOS

Parameter	PCOD	PCOS / PMOS
Nature	Ovarian disorder	Endocrine-metabolic syndrome
Severity	Mild clinical presentation	Severe clinical presentation
Hormonal Imbalance	Mild dysregulation	Significant dysregulation
Ovulation	Frequent ovulation	Frequent anovulation
Insulin Resistance	Low prevalence	Highly prevalent
Infertility Risk	Moderate risk	Elevated risk
Obesity Association	Variable correlation	Strong correlation
Metabolic Syndrome	Lower prevalence	Common
Cardiovascular Risk	Reduced risk	Increased risk
Long-Term Complications	Limited complications	Significant complications

Pathophysiology of PMOS

Neuroendocrine Dysregulation (The HPO Axis)

1. Neuroendocrine Dysregulation (The HPO Axis)

At the level of the hypothalamus and anterior pituitary, the normal pulsatile release of Gonadotropin-Releasing Hormone (GnRH) demonstrates an accelerated pulse frequency [31].

- **Increased GnRH Pulse Frequency:** This rapid pulsing preferentially stimulates the anterior pituitary to secrete Luteinizing Hormone (LH) while relative levels of Follicle-Stimulating Hormone (FSH) maintain constant or subnormal levels [32].
- **Elevated LH-to-FSH Ratio:** The resulting high LH-to-FSH ratio, typically 2:1 or 3:1, alters normal follicular maturation[33]. Continuous LH stimulation exerts a sustained trophic effect on ovarian theca cells [34].

2. Ovarian Hyperandrogenism & Follicular Arrest

The structural and hormonal changes within the ovary occur directly due to this gonadotropin mismatch [35]:

- **Theca Cell Hyperplasia:** Driven by chronic elevation of LH, theca cells undergo hyperplasia and upregulate key steroidogenic enzymes (such as CYP17A1). This shifts the pathway toward elevated androgen synthesis, primarily androstenedione and testosterone.
- **Impaired Granulosa Cell Function:** Suboptimal FSH levels impair granulosa cell aromatase production. This prevents efficient local androgen conversion to estrogens.
- **Follicular Arrest:** Low androgen levels promote early follicular growth. However, elevated intrafollicular androgen levels inhibit dominant follicle selection. Follicles become arrested in the pre-antral and antral stages (measuring 2–9 mm). This clearly creates the classic "string of pearls" peripheral distribution observable on ultrasound imaging. The absence of a dominant follicle inhibits the monthly mid-cycle LH surge. This subsequently prevents ovulation, resulting in chronic anovulation or oligovulation.

3. Metabolic Dysfunction & Insulin Resistance

The metabolic component is a core driver of the syndrome, affecting >70% of patients irrespective of body mass index (BMI).

- **Peripheral Insulin Resistance:** Skeletal muscle and adipose tissue exhibit a post-receptor signaling defect. This impairs glucose transport via Glucose Transporter Type 4 (GLUT-4) transporters. Pancreatic compensation induces increased insulin production, resulting in chronic hyperinsulinemia.
- **Synergistic Action on the Ovary:** Excess circulating insulin functions as a co-gonadotropin. Insulin binds to both insulin receptors and Insulin-like Growth Factor-1 (IGF-1) receptors on theca cells. This action amplifies theca cell responsiveness to LH, consequently increasing androgen synthesis.
- **Suppression of SHBG:** High insulin levels inhibit the hepatic synthesis of Sex Hormone-Binding Globulin (SHBG). Reduced systemic SHBG levels decrease bound circulating androgens. This effect causes an elevation in biologically active free testosterone, which drives clinical symptoms like hirsutism and male-pattern alopecia.

Clinical Presentation & Phenotypes

1. Reproductive & Ovulatory Dysfunction

HPO axis disruptions manifest as irregular menstrual patterns and fertility challenges, primarily driven by follicular arrest.

- Oligomenorrhea or Amenorrhea: Presentation involves oligomenorrhea (< 8 menstrual periods/year) or secondary amenorrhea (menstruation absence for 3–6 consecutive months), indicating chronic anovulation or oligovulation.
- Dysfunctional Uterine Bleeding (DUB): Unopposed endometrial estrogen proliferation, absent regular progesterone withdrawal, induces unpredictable, heavy, or prolonged bleeding episodes.
- Anovulatory Infertility: The lack of dominant mature follicles designates this syndrome as the leading cause of female ovulatory infertility.
- Polycystic Ovarian Morphology (PCOM): Pelvic ultrasound frequently reveals ovaries exhibiting increased volume (> 10 mL) and/or ≥ 12 antral follicles (2–9 mm diameter) peripherally arranged around an echogenic stroma.

2. Cutaneous Manifestations of Hyperandrogenism

Elevated systemic free testosterone and dihydrotestosterone (DHT) concentrations directly impact pilosebaceous units and dermal structures.

- **Hirsutism:** Visually verified excess terminal hair growth in a male-pattern distribution, objectively quantified using the Modified Ferriman-Gallwey (mFG) score (typically ≥ 4 to 8 confirms clinical parameters).
- **Acne Vulgaris:** Persistent, inflammatory acne along the lower face, jawline, and neck, highly refractory to conventional topical treatment.
- **Androgenetic Alopecia:** Progressive hair thinning primarily at the vertex and midline scalp, keeping the frontal hairline.
- **Acanthosis Nigricans:** Hyperpigmented, velvety hyperkeratotic plaques within flexural areas (axillae, neck, groin). This serves as a direct marker of severe insulin resistance, resulting from hyperinsulinemia binding to keratinocyte and fibroblast IGF-1Rs to induce proliferation.

3. Metabolic & Systemic Features

The metabolic axis represents an intrinsic syndrome component that leads to cardiometabolic abnormalities and significantly increases long-term cardiovascular risks.

- Centripetal Obesity: Visceral adiposity and a high waist-to-hip ratio driven by altered insulin and adipokine paths.
- Impaired Glucose Tolerance & T2DM: Peripheral insulin resistance significantly elevates the downstream risk for IGT and early-onset Type 2 Diabetes.
- Metabolic Syndrome: Presents as a cluster of abdominal obesity, elevated blood pressure, and atherogenic dyslipidemia (elevated triglycerides, low HDL-C).
- Obstructive Sleep Apnea (OSA): Occurs frequently with obesity; high androgen metrics alter upper airway configuration, compounding risk profiles.

Table 2: Association of Symptoms to Disease

Clinical Domain	Primary Features	Key Objective Markers / Tools
Reproductive	Oligo/amenorrhea, subfertility, irregular heavy bleeding].	Menstrual tracking, Pelvic Ultrasound (antral follicle count).
Dermatological	Hirsutism, severe acne, male-pattern baldness, acanthosis nigricans.	Modified Ferriman-Gallwey (mFG) scale, Total/Free Testosterone, SHBG.
Metabolic	Visceral obesity, rapid weight gain, acanthosis nigricans.	Fasting Insulin, 2-hour Oral Glucose Tolerance Test (OGTT), Lipid Profile.

Clinical Target	Conventional First-Line	Integrative & Lifestyle Partners
Insulin Resistance	Metformin	Low-GL Diet, Resistance Training, Berberine, Inositols.
Hyperandrogenism	Oral Contraceptives, Spironolactone.	Spearmint tea (anti-androgenic agent), Zinc, Weight loss ($\ge 5 ext{--}10\%$).
Anovulation / Infertility	Letrozole, Clomiphene Citrate.	Myo-Inositol, Melatonin (oocyte quality), Stress reduction.
Chronic Inflammation	Statin therapy (if dyslipidemic)	Omega-3 fatty acids, Curcumin, Mediterranean dietary pattern.

The Ayurvedic Lens: Santarpana-uttha Vyadhi

In Ayurveda, PMOS is not viewed as a single disease entity. It is classified as a complex Santarpana-uttha Vyadhi (a disease born of over-nutrition and metabolic sluggishness) involving a Kapha-Meda predominance. This imbalance causes Srotorodha (microchannel occlusion) in the Artava Vaha Srotas (the female reproductive channels), ultimately leading to Vata Vaishamya (ovulatory dysfunction).

Ayurveda describes follicular growth as a Kapha-mediated process due to its Upachaya property of development. Vata governs differentiation and rupture, enabling ovulation and normal menses. In PMOS, vitiated Kapha impairs follicle development, while vitiated Vata causes premature luteinization leading to anovulation. Pitta is suppressed by the dominance of Vata and Kapha, reducing aromatization and resulting in androgen excess and follicular arrest. This doshic imbalance first disturbs ovarian function and subsequently causes menstrual irregularity.

As per Ayurvedic classics, Rasavaha Srotas becomes vitiated due to consumption of heavy, cold, and excessively unctuous foods, overeating, intake of incompatible food items, and chronic stress. Examples include regular use of cheese, fast food, bakery products, Chinese food, cold beverages, and oily preparations. Mental factors like Chinta or prolonged worry are also considered significant causes of Srotas Dushti.

As per Ayurveda, Medovaha Srotas becomes vitiated by Avyayama, Diwaswapna, overconsumption of fatty foods, and excessive intake of alcohol. Sedentary lifestyle, sleeping during the day, regular intake of lipid-rich and unctuous food, and chronic alcohol use are considered the primary etiological factors for impairment of Medovaha channels.

Ayurveda, menstrual irregularities are described under Artava Vyapad and Yoniroga. Anovulation is correlated with Vandhya or infertility. Obesity is termed Sthoulya, a disorder caused by Santarpana. Dermatological features such as acne and baldness are explained as Mukhadooshika and Khalitya respectively, with separate patho-genesis. Hyperinsulinemia leading to type 2 diabetes mellitus is described under Prameha and is also recognized as a complication of Sthoulya.

Pushpaghni, the primary vitiated Doshas are Kapha with Vriddhi and Vata with Vaigunya.

Purvaroopa - Early prodromal stage before disease manifests. Purvaroopa refers to the prodromal phase that precedes the full manifestation of a disease. It is the initial warning stage where subtle clinical signs appear before overt pathology develops. In PMOS, early indicators such as mild weight gain, slight irregular cycles, and minor skin changes can be considered Purvaroopa. Subtle disturbances like scanty menstruation, mild hirsutism, and early metabolic shifts act as Purvaroopa of PMOS. Purvaroopa serves as an early diagnostic clue, indicating the impending onset of disease before severe symptoms appear.

Table 3: Clinical Feature Correlations

Modern Clinical Feature	Ayurvedic Correlation	Description / Clinical Meaning
Prodromal signs	Purvaroopa	Premonitory metabolic or systemic warning signs.
Anovulation	Artava Dushti	Alteration or dysfunction of the ovum and follicular maturity.
Amenorrhea / Oligomenorrhea	Artava Dushti / Yoniroga	Complete absence or severe irregularity of the menstrual cycle.
Obesity	Sthoulya	Accumulation of visceral adiposity and tissue sluggishness (Kapha-Meda).
Acne	Mukhadooshika	Inflammatory facial skin eruptions driven by hyperandrogenism.

Ayurvedic Pathogenesis & Clinical Correlations

1. Srotas & Dushya Dushti (Tissue & Channel Vitiation)

- Involved Channels: The pathogenesis spans the Rasavaha, Raktavaha, Mamsavaha, Medovaha, Swedavaha, and Artavaha Srotas.
- Clinical Manifestations (Lakshanas):
  - Rasa Dushti: Loss of appetite, heaviness, drowsiness, loss of digestive fire, body ache, channel obstruction, and impotence.
  - Rakta Dushti: Skin disorders, eruptions, and abnormal uterine bleeding.
  - Mamsa Dushti: Formation of cystic swellings or Granthi.
  - Meda Dushti: Associated with Prameha (metabolic/urinary disorders) and its prodromal features.
  - Asthi Dushti: Hair and body hair abnormalities.
  - Majja Dushti: Systemic heaviness.
  - Shukra Dushti: Impotence and recurrent miscarriage.
- Modern Correlation: Rasa and Meda involvement directly correlates with insulin resistance and obesity. Vata Avarana (occlusion) by Kapha disrupts the normal negative feedback mechanism of the HPO axis, driving hyperandrogenism. Artava Dushti manifests clinically as irregular or anovulatory menstrual cycles, while Beeja Upaghata represents the hereditary/genetic component of the disease.

2. Srotodushti Patterns & Samprapti (Pathogenic Mechanisms)

- Srotodushti Profiles: Three distinct structural channel abnormalities occur:
  - Sanga (Obstruction): Kapha obstruction of Vata and Pittavaha pathways blocks regular menstrual flow, causing amenorrhea and oligomenorrhea.
  - Atipravarti (Excess Flow): Aggravated Pitta drives abnormal uterine bleeding.
  - Granthi (Cystic Growth): Corresponds to the structural development of polycystic ovaries.
- Samprapti via Jatharagni Mandhya: Consumption of Kapha-increasing diet and lifestyle factors weakens the primary digestive fire (Jatharagni).
  - This weakness results in an increased Snehansha (unctuousness/ fat) in the body, which diminishes Pitta, affecting skin luster and causing Karshyam (acanthosis nigricans).
  - Weakened Jatharagni precipitates tissue (Dhatu) depletion alongside an excessive production of metabolic wastes (Mala), including Kesha (hair) from Asthi, Sweda (sweat) from Majja, and excess sebum causing inflammatory acne.
  - The accumulation of Ama (undigested metabolic toxins) causes severe Vata derangement. The resulting Vata-Kapha obstruction in the Artavaha Srotas culminates in oligomenorrhea or amenorrhea.
- Samprapti via Sthula & Medovaha Dushti: Vitiation of the Medovaha Srotas at its anatomical roots within the pelvic region causes a direct dysfunction of Apana Vayu, significantly impairing downstream menstrual flow.

3. Classical Gynecological Correlations (Yoni Vyapad & Jataharini)

- Artava Kshaya – Su. Sa. Sutra Sthana 15/12: Described in Sushruta Samhita as a state of deficient or reduced menstrual flow. Its primary presentation includes primary or secondary amenorrhea, termed Yathochita Kala Adarshanam, alongside scanty menses (hypomenorrhea).
- Shandi Yoni Vyapad – S.S.Ut. 38/18-20: Characterized by primary amenorrhea (Anartava), underdeveloped breasts (Astana), and a distinctly rough vaginal canal, though the individual remains capable of sexual intercourse.
- Bandhya Yoni Vyapad – S.S.Ut. 38/10-11: Differentiated from Shandi by the presence of normal breast development. It presents with amenorrhea, where Nastratava points to the structural destruction of Artava during embryonic/fetal life.
- Vikuta Jataharini – Ka.S.K. 6/34-35: Described in Kashyapa Samhita as presenting with highly irregular menstrual cycles,

oligomenorrhea, scanty menses, or episodes of excessive menstrual bleeding accompanied by metabolic disturbances and general debility/weakness.

- Pushpaghni Jataharini – Ka.S.K. 6/32-33: A condition where the menstrual cycle occurs in a timely, regular fashion but is completely non-productive (Vritha Pushpam), explicitly denoting an anovulatory cycle where the woman is unable to conceive. Its classic physical indicators include a stout, corpulent build and hirsutism, specifically noted as hairy cheeks.

Core Clinical Principles (Chikitsa Sutra)

The therapeutic protocol primarily aims to correct Agni (metabolic fire) and eliminate Srotorodha (channel obstruction) to restore regular Artava Pravritti (menstruation/ovulation) :

- **Nidana Parivarjana (Etiological Avoidance):** Immediate cessation of Ahita Ahara (processed, high-sugar, inflammatory foods) and Vihara (daytime sleeping, sedentary habits) to halt further Ama generation.
- **Agni Deepana & Ama Pachana (Metabolic Reset):** Ignition of central and tissue-level metabolic fire (Dhatvagni) to eliminate circulating metabolic toxins (Ama).
- **Kapha-Meda Hara Chikitsa (Antiadiposity Therapy):** Downregulation of excess lipids and fluid retention to directly combat visceral cellular insulin resistance.
- **Srotoshodhana & Vatanulomana (Channel Clearance):** Clearance of microchannel structural blockages; correction of Apana Vata downward movement facilitates regular ovulation.
- **Artava Janana (Ovarian Stimulation):** Application of phytoestrogenic and ovulatory-inducing agents restores normal follicular maturation.

Panchakarma & Bio-Purification

These aggressive, structured bio-purification protocols are distinct from relaxation therapies and are designed to reset the neuroendocrine axis:

- **Udvartana (Dry Herbal Scraping):** Upward therapeutic massage using dry, warming herbal powders like Kolakulathadi Churna. It stimulates subcutaneous circulation, mobilizes stagnant Meda (adipose tissue), and downregulates peripheral insulin resistance.
- **Virechana (Therapeutic Purgation):** Induced purgation utilizing Sukumar Eranda Taila or Trivrit Lehya, carefully scheduled during the late follicular phase. It serves as a first-line therapy for Pitta and Rakta vitiation [85], purging hepatic toxins, normalizing lipid metabolism, and modulating the central HPO axis to reduce elevated LH levels.
- **Basti (Medicated Enema Therapy):** Alternating cycles of Niruha (decoction enemas like Dashamoola Triphaladi) and Anuvasana (oil enemas like Sahacharadi Taila). It stands as the absolute gold standard for governing Apana Vata, improving endometrial receptivity, and aiding follicular rupture.
- **Nasya (Intranasal Drug Delivery):** Instillation of medicated oils (Anu Taila or Kumkumadi Taila) through the nasal passages. Because the nasal mucosa offers a direct pathway to the cribriform plate, Nasya exerts a central neuroendocrine effect, directly regulating hypothalamic GnRH pulsatility.

Yoga Interventions

Asana Protocol (Pelvic Congestion Relief & Insulin Disposal)

- Surya Namaskar (Dynamic): Accelerates basal metabolic rate, aids visceral adipose tissue mobilization, and improves global insulin sensitivity.
- Baddha Konasana & Upavistha Konasana: Directly increases pelvic floor perfusion and arterial blood flow; this relieves local Srotorodha and structural ovarian congestion.
- Bhujangasana & Setu Bandhasana: Exerts targeted intra-abdominal pressure profiles, stimulating adrenal and thyroid glands. This optimizes global endocrine balance.

Pranayama & Meditation (HPO Axis Stabilization)

- Nadi Shodhana (Alternate Nostril Breathing): Shifts autonomic tone from sympathetic to parasympathetic dominance. This lowers chronic cortisol output, a central suppressor of LH/FSH coordination.
- Bhramari Pranayama (Humming Bee Breath): Increases endogenous nitric oxide production and balances the hypo-thalamic-pituitary-adrenal (HPA) axis via targeted acoustic vibrations. This mitigates stress-induced hyperandrogenism.

Complementary Modalities Overview

HPO Axis Regulation: Clinical studies evaluating structured yoga protocols in patients with reproductive endocrine disorders indicate a down-regulation of sympathetic tone and a reduction in serum LH levels and LH-to-FSH ratios.

- **Autonomic Balance:** By increasing vagal nerve stimulation and enhancing parasympathetic dominance, regular practice reduces the central stress response, thereby reducing cortisol-driven insulin resistance.

REFERENCES

1. Tiwari A, Mathur P. PMOS as a lifestyle disorder through Ayurvedic lens. Int J Ayurvedic Med. 2023;14(2):285-297.
2. Balen AH. The pathogenesis of polycystic ovary syndrome: the interplay of insulin resistance and obesity. Reprod Biomed Online. 2002;4(3):281-289. doi:10.1016/S1472-6483(10)61115-6
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. doi:10.1016/j.fertnstert.2003.10.004
4. Ehrman DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism of polycystic ovary syndrome type by gonadotropin-releasing hormone agonist testing. N Engl J Med. 1995;332(10):639-646. doi:10.1056/NEJM199503093321004
5. Azziz R. Controversy in clinical endocrinology: how should the polycystic ovary syndrome be defined? J Clin Endocrinol Metab. 2014;99(11):4012-4017. doi:10.1210/jc.2014-2166
6. Witchel SF, Oberfield SE, Pena AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment across the lifespan. Pediatrics. 2022;149(5):e2021051786. doi:10.1542/peds.2021-051786
7. Jacobs HS. Polycystic ovary syndrome: etiology and management. Gynecol Endocrinol. 1987;1(2):113-131.
8. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest. 1976;57(5):1320-1329. doi:10.1172/JCI108399
9. Li R, et al. Neuroendocrine mechanisms of reproductive axis failure in hyperandrogenic states. J Endocrinol. 2014;221(3):105-117.
10. Wang Y, et al. Hyperandrogenism and HPO axis disruption in syndromic endocrine paradigms. Endocr Connect. 2023;12(4):e220412.
11. Morava E, et al. Network medicine and systems biology approaches to multi-systemic metabolic network failures. J Inherit Metab Dis. 2015;38(2):211-222.
12. Caldwell AS, et al. Neuroendocrine and metabolic cross-talk in PCOS models. Endocrinology. 2017;158(4):1120-1132. doi:10.1210/en.2016-1845
13. Dumesic DA, et al. The 1990 National Institutes of Health criteria for polycystic ovary syndrome: a retrospective review. Fertil Steril. 2008;89(6):1420-1428.
14. INSERM. Clinical nosology and distinct pathological entities. French National Institute of Health Framework. 2020.
15. Hucklenbroich P. The epistemological concept of disease vs syndrome. Theor Med Bioeth. 2014;35(4):261-275.
16. Balen AH, et al. The string of pearls sign: transvaginal ultrasound definitions of antral follicle distribution. Hum Reprod Update. 2003;9(6):505-514.
17. Genazzani AR, Genazzani AD. Peripheral insulin resistance across variable body mass indices in endocrine dysfunction. Gynecol Endocrinol. 2023;39(1):1987542.
18. Shirazi M, et al. Skeletal muscle post-receptor signaling defects and GLUT-4 transport inhibition. Cell Metab. 2021;33(5):980-993.
19. Dunaif A, et al. Pancreatic compensation and chronic hyperinsulinemia in syndromic insulin resistance. Diabetes. 1995;44(10):1130-1141.
20. Goodyear LJ, Kahn BB. Exercise as a non-pharmacological insulin sensitizer: GLUT-4 translocation mechanisms in skeletal muscle. Annu Rev Med. 1998;49:235-261.
21. Ibáñez L, et al. Resistance training vs aerobic cardiorespiratory fitness pathways in expanding visceral fat disposal capacity. J Clin Endocrinol Metab. 2005;90(4):2110-2116.
22. Monastra G, et al. Combining myo-inositol and d-chiro-inositol in the 40:1 ratio: a physiological approach to PMOS therapy. Gynecol Endocrinol. 2021;37(4):291-296. doi:10.1080/09513590.2020.1832014
23. Pandey S, Gupta R. Rasa-Virya-Vipaka profiles of classical herbs acting as metabolic and steroidogenic regulators. Ayurveda Pharmacodynamics. 2026;11(1):45-58.
24. Anti-Androgenic Effect of Symplocos Racemosa Roxb. against Letrozole Induced Polycystic Ovary Using Rat Model. J Ethnopharmacol. 2013;150(1):109-115.
25. Носенко О, et al. Symplocos racemosa extracts in the restoration of the LH-to-FSH ratio and serum testosterone reduction. Reprod Med. 2023;14(2):22-31.
26. Jayasumana M, Karunarathne W. Phytoestrogenic and ovulatory stimulant targets of Anethum sowa. Phytomedicine. 2023;112:154620.
27. S R, et al. Shatapushpa Churna in regular follicular maturation induction. J Indian Sys Med. 2026;14(1):12-19.
28. Alinejad-Mofrad S, et al. Clinical evaluation of Aloe vera (Kumari) as an insulin sensitizer in metabolic conditions. J Diabetes Metab Disord. 2015;14:22.
29. Shin S, et al. Upregulation of peripheral glucose utilization and systemic anti-inflammatory actions of Aloe vera gel components. Phytother Res. 2011;25(11):1591-1599.
30. Memon A. Guduchi cell-level pathway regulation in state-level metabolic resistance. Int J Alternative Med. 2026;24(1):89-96.
31. Mishra A, et al. Cellular insulin sensitivity improvements via Tinospora cordifolia aqueous extracts. Phytomedicine. 2023;115:154810.
32. Purohit S, et al. Bauhinia variegata (Kanchanara) pharmacodynamics as a lymphatic stimulant and Granthi-hara agent. J Ethnopharmacol. 2022;293:115240.
33. Hamid S, et al. Triphala formula metabolic scraping (Lekhana) mechanisms. Ayurveda Res. 2013;4(2):112-119.
34. Phimarn W, et al. Triphala supplementation impacts on dyslipidemia, intestinal Ama clearing, and visceral adiposity index parameters: a trial. Complement Ther Med. 2022;68:102841.
35. Swathi P, et al. Waist-to-hip ratio corrections and anti-hyperlipidemic activity of Triphala formulations. Int J Ayurvedic Med. 2021;12(3):540-549.